{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:17:33Z","timestamp":1791217053034,"version":"4.1.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T00:00:00Z","timestamp":1144368000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1038\/nri1838","type":"journal-article","created":{"date-parts":[[2006,4,19]],"date-time":"2006-04-19T06:22:54Z","timestamp":1145427774000},"page":"394-403","source":"Crossref","is-referenced-by-count":424,"title":["B-cell targeting in rheumatoid arthritis and other autoimmune diseases"],"prefix":"10.1038","volume":"6","author":[{"given":"Jonathan C. W.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Cambridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,4,7]]},"reference":[{"key":"BFnri1838_CR1","first-page":"1590","volume":"51","author":"J Donath","year":"1904","unstructured":"Donath, J. & Landsteiner, K. \u00dcber paroxysmale H\u00e4moglobinurie. M\u00fcnchener Medizinische Wochenschrift 51, 1590\u20131593 (1904).","journal-title":"M\u00fcnchener Medizinische Wochenschrift"},{"key":"BFnri1838_CR2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1699-0463.1940.tb01475.x","volume":"17","author":"E Waaler","year":"1940","unstructured":"Waaler, E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol. Microbiol. Scand. 17, 172\u2013188 (1940).","journal-title":"Acta Pathol. Microbiol. Scand."},{"key":"BFnri1838_CR3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(81)91107-7","volume":"2","author":"G Janossy","year":"1981","unstructured":"Janossy, G. et al. Rheumatoid arthritis: a disease of T lymphocyte\u2013macrophage immunoregulation. Lancet 2, 839\u2013842 (1981). This paper established the prevailing view of the 1980s and 1990s; that rheumatoid arthritis is a T-cell-driven disease.","journal-title":"Lancet"},{"key":"BFnri1838_CR4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/asheducation-2005.1.74","volume":"2005","author":"DL Kastner","year":"2005","unstructured":"Kastner, D. L. Hereditary periodic fever syndromes. Hematology (Am. Soc. Hematol. Educ. Program) 2005, 74\u201381 (2005).","journal-title":"Hematology (Am. Soc. Hematol. Educ. Program)"},{"key":"BFnri1838_CR5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM197804202981602","volume":"298","author":"P Stastny","year":"1978","unstructured":"Stastny, P. Association of the B lymphocyte alloantigen DRw4 with rheumatoid arthritis. N. Engl. J. Med. 298, 869\u2013872 (1978). This seminal study showed that rheumatoid arthritis arises from both genetic and acquired factors. Of interest, HLA-DR4 was first described as a 'B-cell alloantigen'.","journal-title":"N. Engl. J. Med."},{"key":"BFnri1838_CR6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0140-6736(73)91360-3","volume":"1","author":"DA Brewerton","year":"1973","unstructured":"Brewerton, D. A. et al. Ankylosing spondylitis and HL-A 27. Lancet 1, 904\u2013907 (1973).","journal-title":"Lancet"},{"key":"BFnri1838_CR7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.immunol.22.012703.104549","volume":"22","author":"AP Manderson","year":"2004","unstructured":"Manderson, A. P., Botto, M. & Walport, M. J. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 22, 431\u2013456 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnri1838_CR8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.gene.6364111","volume":"5","author":"ID Arnott","year":"2004","unstructured":"Arnott, I. D. et al. NOD2\/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun. 5, 417\u2013425 (2004).","journal-title":"Genes Immun."},{"key":"BFnri1838_CR9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2567.1999.00772.x","volume":"97","author":"JC Edwards","year":"1999","unstructured":"Edwards, J. C., Cambridge, G. & Abrahams, V. M. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 97, 188\u2013196 (1999). This review outlines the concept of self-perpetuating autoreactive B cells, on which B-cell-depletion therapy in rheumatoid arthritis was based.","journal-title":"Immunology"},{"key":"BFnri1838_CR10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/35100573","volume":"1","author":"MJ Shlomchik","year":"2001","unstructured":"Shlomchik, M. J., Craft, J. E. & Mamula, M. J. From T to B and back again; positive feedback in systemic autoimmune disease. Nature Rev. Immunol. 1, 147\u2013153 (2001). This review outlines the concept of a cycle of B-cell\u2013T-cell interactions in autoimmunity from the perspective of T-cell initiation.","journal-title":"Nature Rev. Immunol."},{"key":"BFnri1838_CR11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.berh.2005.05.006","volume":"19","author":"JH Anolik","year":"2005","unstructured":"Anolik, J. H. & Aringer, M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract. Res. Clin. Rheumatol. 19, 859\u2013878 (2005).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnri1838_CR12","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards, J. C. et al. Efficacy of B cell targeted therapy with rituximab, in rheumatoid arthritis. N. Engl. J. Med. 350, 2572\u20132581 (2004). This paper reported the randomized controlled clinical trial that established the efficacy of B-cell-depletion therapy in rheumatoid arthritis.","journal-title":"N. Engl. J. Med."},{"key":"BFnri1838_CR13","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge, G. et al. Serological changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48, 2146\u20132154 (2003). This paper describes the pharmacodynamics of B-cell depletion in rheumatoid arthritis in terms of circulating B-cell numbers, autoantibody levels and clinical response.","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1074-7613(04)00112-8","volume":"20","author":"F Martin","year":"2004","unstructured":"Martin, F. & Chan, A. Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity 20, 517\u2013527 (2004).","journal-title":"Immunity"},{"key":"BFnri1838_CR15","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.4049\/jimmunol.167.7.3610","volume":"167","author":"JO Bohnhorst","year":"2001","unstructured":"Bohnhorst, J. O., Bjorgan, M. B., Thoen, J. E., Natvig, J. B. & Thompson, K. M. Bm1\u2013Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J. Immunol. 167, 3610\u20133618 (2001).","journal-title":"J. Immunol."},{"key":"BFnri1838_CR16","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.4049\/jimmunol.152.8.3760","volume":"152","author":"G Koopman","year":"1994","unstructured":"Koopman, G. et al. Adhesion through the LFA-1 (CD11a\/CD18)\u2013ICAM-1 (CD54) and the VLA-4 (CD49d)\u2013VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J. Immunol. 152, 3760\u20133767 (1994).","journal-title":"J. Immunol."},{"key":"BFnri1838_CR17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000082106","volume":"8","author":"F Mackay","year":"2005","unstructured":"Mackay, F., Sierro, F., Grey, S. T. & Gordon, T. P. The BAFF\/APRIL system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 8, 243\u2013265 (2005).","journal-title":"Curr. Dir. Autoimmun."},{"key":"BFnri1838_CR18","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1126\/science.1061965","volume":"293","author":"JS Thompson","year":"2001","unstructured":"Thompson, J. S. et al. BAFF-R, a novel TNF receptor that specifically interacts with BAFF. Science 293, 2108\u20132111 (2001).","journal-title":"Science"},{"key":"BFnri1838_CR19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/smim.1997.0078","volume":"9","author":"IC MacLennan","year":"1997","unstructured":"MacLennan, I. C., Casamayor-Palleja, M., Toellner, K. M., Gulbranson-Judge, A. & Gordon, J. Memory B-cell clones and the diversity of their members. Semin. Immunol. 9, 229\u2013234 (1997).","journal-title":"Semin. Immunol."},{"key":"BFnri1838_CR20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.iy.13.040195.001015","volume":"13","author":"DT Fearon","year":"1995","unstructured":"Fearon, D. T. & Carter, R. H. The CD19\/CR2\/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu. Rev. Immunol. 13, 127\u2013149 (1995).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnri1838_CR21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0165-2478(03)00078-6","volume":"88","author":"B Heyman","year":"2003","unstructured":"Heyman, B. Feedback regulation by IgG antibodies. Immunol. Lett. 88, 157\u2013161 (2003).","journal-title":"Immunol. Lett."},{"key":"BFnri1838_CR22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/416603a","volume":"416","author":"EA Leadbetter","year":"2002","unstructured":"Leadbetter, E. A. et al. Chromatin\u2013IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603\u2013607 (2002).","journal-title":"Nature"},{"key":"BFnri1838_CR23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1084\/jem.173.2.487","volume":"173","author":"E Roosnek","year":"1991","unstructured":"Roosnek, E. & Lanzavecchia, A. Efficient and selective presentation of antigen\u2013antibody complexes by rheumatoid factor B cells. J. Exp. Med. 173, 487\u2013489 (1991). This paper provides perhaps the first clear in vitro demonstration that B cells and T cells of different affinities can interact in unusual ways.","journal-title":"J. Exp. Med."},{"key":"BFnri1838_CR24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/rheumatology\/37.2.126","volume":"37","author":"JC Edwards","year":"1998","unstructured":"Edwards, J. C. & Cambridge, G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br. J. Rheumatol. 37, 126\u2013130 (1998).","journal-title":"Br. J. Rheumatol."},{"key":"BFnri1838_CR25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/0-387-24534-0_21","volume-title":"Molecular Autoimmunity","author":"JC Edwards","year":"2005","unstructured":"Edwards, J. C., Cambridge, G. & Leandro, M. J. in Molecular Autoimmunity (ed. Zouali, M.) 291\u2013309 (Springer, New York, 2005)."},{"key":"BFnri1838_CR26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0307-742X(21)00604-4","volume":"11","author":"M Mannik","year":"1985","unstructured":"Mannik, M. & Nardella, F. A. IgG rheumatoid factors and self-association of these antibodies. Clin. Rheum. Dis. 11, 551\u2013572 (1985).","journal-title":"Clin. Rheum. Dis."},{"key":"BFnri1838_CR27","first-page":"444","volume-title":"Pathological Basis of Connective Tissue Diseases","author":"DL Gardner","year":"1992","unstructured":"Gardner, D. L. in Pathological Basis of Connective Tissue Diseases (ed. Gardner, D. L.) 444\u2013526 (Edward Arnold, London, 1992)."},{"key":"BFnri1838_CR28","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/art.20316","volume":"50","author":"FA van Gaalen","year":"2004","unstructured":"van Gaalen, F. A. et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 50, 2113\u20132121 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/ar110","volume":"2","author":"JC Edwards","year":"2000","unstructured":"Edwards, J. C. Development and differentiation of synovial fibroblasts in arthritis. Arthritis Res. 2, 344\u2013347 (2000).","journal-title":"Arthritis Res."},{"key":"BFnri1838_CR30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1699-0463.1997.tb00567.x","volume":"105","author":"RN Maini","year":"1997","unstructured":"Maini, R. N., Elliott, M., Brennan, F. M., Williams, R. O. & Feldmann, M. TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. APMIS 105, 257\u2013263 (1997).","journal-title":"APMIS"},{"key":"BFnri1838_CR31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.1780330602","volume":"33","author":"GS Firestein","year":"1990","unstructured":"Firestein, G. S. & Zvaifler, N. J. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 33, 768\u2013773 (1990).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1365-2567.1998.00491.x","volume":"94","author":"A Bhatia","year":"1998","unstructured":"Bhatia, A., Blades, S., Cambridge, G. & Edwards, J. C. Differential distribution of Fc\u03b3RIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenviroments. Immunology 94, 56\u201363 (1998).","journal-title":"Immunology"},{"key":"BFnri1838_CR33","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/1529-0131(200003)43:3<608::AID-ANR18>3.0.CO;2-G","volume":"43","author":"VM Abrahams","year":"2000","unstructured":"Abrahams, V. M., Cambridge, G. & Edwards, J. C. Induction of tumour necrosis factor \u03b1 production by human monocytes: a key role for Fc\u03b3RIIIa in rheumatoid arthritis. Arthritis Rheum. 43, 608\u2013616 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/ni772","volume":"3","author":"I Matsumoto","year":"2002","unstructured":"Matsumoto, I. et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nature Immunol. 3, 360\u2013365 (2002).","journal-title":"Nature Immunol."},{"key":"BFnri1838_CR35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","volume":"29","author":"AJ Grillo-Lopez","year":"2002","unstructured":"Grillo-Lopez, A. J., Hedrick, E., Rashford, M. & Benyunes, M. Rituximab: ongoing and future clinical development. Semin. Oncol. 29, 105\u2013112 (2002). An important review of the development of rituximab as a clinical therapeutic agent.","journal-title":"Semin. Oncol."},{"key":"BFnri1838_CR36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","volume":"8","author":"MS Cragg","year":"2005","unstructured":"Cragg, M. S., Walshe, C. A., Ivanov, A. O. & Glennie, M. J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8, 140\u2013174 (2005).","journal-title":"Curr. Dir. Autoimmun."},{"key":"BFnri1838_CR37","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","volume":"199","author":"J Uchida","year":"2004","unstructured":"Uchida, J. et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659\u20131669 (2004).","journal-title":"J. Exp. Med."},{"key":"BFnri1838_CR38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","volume":"48","author":"JH Anolik","year":"2003","unstructured":"Anolik, J. H. et al. The relationship of Fc\u03b3RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48, 455\u2013459 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR39","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","volume":"171","author":"N Di Gaetano","year":"2003","unstructured":"Di Gaetano, N. et al. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171, 1581\u20131587 (2003).","journal-title":"J. Immunol."},{"key":"BFnri1838_CR40","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","volume":"104","author":"JL Teeling","year":"2004","unstructured":"Teeling, J. L. et al. Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood 104, 1793\u20131800 (2004).","journal-title":"Blood"},{"key":"BFnri1838_CR41","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","volume":"174","author":"Q Gong","year":"2005","unstructured":"Gong, Q. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817\u2013826 (2005). This paper provides detailed recent insights into the mechanisms of B-cell killing by rituximab.","journal-title":"J. Immunol."},{"key":"BFnri1838_CR42","unstructured":"Edwards, J. C., Leandro, M. J. & Cambridge, G. B lymphocyte depletion therapy in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. (in the press)."},{"key":"BFnri1838_CR43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"JC Edwards","year":"2001","unstructured":"Edwards, J. C. & Cambridge, G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40, 205\u2013211 (2001).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnri1838_CR44","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","volume":"61","author":"MJ Leandro","year":"2002","unstructured":"Leandro, M. J., Edwards, J. C. & Cambridge, G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. 61, 883\u2013888 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnri1838_CR45","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro, M. J., Ehrenstein, M. R., Cambridge, G. & Edwards, J. C. Repopulation of B lymphocytes in peripheral blood following B lymphocyte depletion with rituximab in rheumatoid arthritis. Arthritis Rheum. 54, 613\u2013620 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ajh.20135","volume":"77","author":"R Swords","year":"2004","unstructured":"Swords, R., Power, D., Fay, M., O'Donnell, R. & Murphy, P. T. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am. J. Hematol. 77, 103\u2013104 (2004).","journal-title":"Am. J. Hematol."},{"key":"BFnri1838_CR47","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","volume":"46","author":"S De Vita","year":"2002","unstructured":"De Vita, S. et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46, 2029\u20132033 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/03009740310004379","volume":"33","author":"C Kneitz","year":"2004","unstructured":"Kneitz, C., Wilhelm, M. & Tony, H. P. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand. J. Rheumatol. 33, 82\u201386 (2004).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnri1838_CR49","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","volume":"167","author":"S Takemura","year":"2001","unstructured":"Takemura, S., Klimiuk, P. A., Braun, A., Goronzy, J. J. & Weyand, C. M. T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. 167, 4710\u20134718 (2001).","journal-title":"J. Immunol."},{"key":"BFnri1838_CR50","doi-asserted-by":"crossref","first-page":"R714","DOI":"10.1186\/ar1731","volume":"7","author":"AS Rouziere","year":"2005","unstructured":"Rouziere, A. S., Kneitz, C., Palanichamy, A., Dorner, T. & Tony, H. P. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res. Ther. 7, R714\u2013R724 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"BFnri1838_CR51","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","volume":"54","author":"G Cambridge","year":"2006","unstructured":"Cambridge, G. et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54, 723\u2013732 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR52","first-page":"S709","volume":"52","author":"P Emery","year":"2005","unstructured":"Emery, P. et al. Rituximab in rheumatoid arthritis: a double blind placebo controlled dose ranging trial. Arthritis Rheum. 52, S709 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR53","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist, S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48, 2741\u20132749 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR54","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","volume":"98","author":"R Stasi","year":"2001","unstructured":"Stasi, R., Pagano, A., Stipa, E. & Amadori, S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98, 952\u2013957 (2001).","journal-title":"Blood"},{"key":"BFnri1838_CR55","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","volume":"125","author":"N Cooper","year":"2004","unstructured":"Cooper, N. et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol. 125, 232\u2013239 (2004).","journal-title":"Br. J. Haematol."},{"key":"BFnri1838_CR56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20276","volume":"78","author":"P Braendstrup","year":"2005","unstructured":"Braendstrup, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am. J. Hematol. 78, 275\u2013280 (2005).","journal-title":"Am. J. Hematol."},{"key":"BFnri1838_CR57","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","volume":"46","author":"MJ Leandro","year":"2002","unstructured":"Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R. & Isenberg, D. A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673\u20132677 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR58","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20592","volume":"50","author":"JH Anolik","year":"2004","unstructured":"Anolik, J. H. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580\u20132589 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/03009740410010227","volume":"33","author":"RF van Vollenhoven","year":"2004","unstructured":"van Vollenhoven, R. F. et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand. J. Rheumatol. 33, 423\u2013427 (2004).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnri1838_CR60","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","volume":"44","author":"MJ Leandro","year":"2005","unstructured":"Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R. & Isenberg, D. A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44, 1542\u20131545 (2005).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnri1838_CR61","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","volume":"44","author":"U Specks","year":"2001","unstructured":"Specks, U., Fervenza, F. C., McDonald, T. J. & Hogan, M. C. E. Response of Wegener's granulomatosis to anti-CD20 chimaeric monoclonal antibody therapy. Arthritis Rheum. 44, 2836\u20132840 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR62","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","volume":"52","author":"KA Keogh","year":"2005","unstructured":"Keogh, K. A., Wylam, M. E., Stone, J. H. & Specks, U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 262\u2013268 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR63","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","volume":"257","author":"P Eriksson","year":"2005","unstructured":"Eriksson, P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. 257, 540\u2013548 (2005).","journal-title":"J. Intern. Med."},{"key":"BFnri1838_CR64","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","volume":"52","author":"TD Levine","year":"1999","unstructured":"Levine, T. D. & Pestronk, A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 52, 1701\u20131704 (1999).","journal-title":"Neurology"},{"key":"BFnri1838_CR65","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1212\/01.WNL.0000098996.02934.86","volume":"61","author":"R Rojas-Garcia","year":"2003","unstructured":"Rojas-Garcia, R. et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology 61, 1814\u20131816 (2003).","journal-title":"Neurology"},{"key":"BFnri1838_CR66","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","volume":"55","author":"F Zaja","year":"2000","unstructured":"Zaja, F., Russo, D., Fuga, G., Perella, G. & Baccarani, M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55, 1062\u20131063 (2000).","journal-title":"Neurology"},{"key":"BFnri1838_CR67","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","volume":"77","author":"A Gajra","year":"2004","unstructured":"Gajra, A., Vajpayee, N. & Grethlein, S. J. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am. J. Hematol. 77, 196\u2013197 (2004).","journal-title":"Am. J. Hematol."},{"key":"BFnri1838_CR68","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine, T. D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 52, 601\u2013607 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR69","first-page":"1369","volume":"32","author":"O Lambotte","year":"2005","unstructured":"Lambotte, O. et al. Efficacy of rituximab in refractory polymyositis. J. Rheumatol. 32, 1369\u20131370 (2005).","journal-title":"J. Rheumatol."},{"key":"BFnri1838_CR70","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.bmt.1703654","volume":"30","author":"P Szabolcs","year":"2002","unstructured":"Szabolcs, P., Reese, M., Yancey, K. B., Hall, R. P. & Kurtzberg, J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 30, 327\u2013329 (2002).","journal-title":"Bone Marrow Transplant."},{"key":"BFnri1838_CR71","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2133.2005.06651.x","volume":"153","author":"MJ Arin","year":"2005","unstructured":"Arin, M. J., Engert, A., Krieg, T. & Hunzelmann, N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br. J. Dermatol. 153, 620\u2013625 (2005).","journal-title":"Br. J. Dermatol."},{"key":"BFnri1838_CR72","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","volume":"101","author":"F Zaja","year":"2003","unstructured":"Zaja, F. et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101, 3827\u20133834 (2003).","journal-title":"Blood"},{"key":"BFnri1838_CR73","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00277-004-0964-6","volume":"84","author":"PS Reddy","year":"2005","unstructured":"Reddy, P. S. et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann. Hematol. 84, 232\u2013235 (2005).","journal-title":"Ann. Hematol."},{"key":"BFnri1838_CR74","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe, J. et al. Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study. Arthritis Rheum. 52, 2740\u20132750 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR75","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2002-03-0765","volume":"100","author":"A Wiestner","year":"2002","unstructured":"Wiestner, A. et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 100, 3426\u20133428 (2002).","journal-title":"Blood"},{"key":"BFnri1838_CR76","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","volume":"62","author":"NL Monson","year":"2005","unstructured":"Monson, N. L., Cravens, P. D., Frohman, E. M., Hawker, K. & Racke, M. K. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch. Neurol. 62, 258\u2013264 (2005).","journal-title":"Arch. Neurol."},{"key":"BFnri1838_CR77","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/archneur.62.10.1641-b","volume":"62","author":"HF Petereit","year":"2005","unstructured":"Petereit, H. F. & Rubbert, A. Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis. Arch. Neurol. 62, 1641\u20131642 (2005).","journal-title":"Arch. Neurol."},{"key":"BFnri1838_CR78","first-page":"1620","volume":"62","author":"O Stuve","year":"2005","unstructured":"Stuve, O. et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol. 62, 1620\u20131623 (2005).","journal-title":"Arch. Neurol."},{"key":"BFnri1838_CR79","first-page":"S645","volume":"50","author":"G Cambridge","year":"2004","unstructured":"Cambridge, G. et al. Serological changes following B cell depletion therapy in SLE. Arthritis Rheum. 50, S645 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR80","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/brain\/120.8.1461","volume":"120","author":"FW Gay","year":"1997","unstructured":"Gay, F. W., Drye, T. J., Dick, G. W. & Esiri, M. M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 120, 1461\u20131483 (1997).","journal-title":"Brain"},{"key":"BFnri1838_CR81","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.cji.0000155050.03916.04","volume":"28","author":"Y Vugmeyster","year":"2005","unstructured":"Vugmeyster, Y. et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J. Immunother. 28, 212\u2013219 (2005).","journal-title":"J. Immunother."},{"key":"BFnri1838_CR82","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.4049\/jimmunol.162.11.6589","volume":"162","author":"D Shan","year":"1999","unstructured":"Shan, D. et al. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J. Immunol. 162, 6589\u20136595 (1999).","journal-title":"J. Immunol."},{"key":"BFnri1838_CR83","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1158\/1078-0432.CCR-04-2290","volume":"11","author":"DA Vallera","year":"2005","unstructured":"Vallera, D. A. et al. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia\/lymphoma. Clin. Cancer Res. 11, 3879\u20133888 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnri1838_CR84","first-page":"S447","volume":"50","author":"J Kaufman","year":"2004","unstructured":"Kaufman, J. et al. Initial clinical study of immunotherapy in SLE using epratuzumab (humanized anti-CD22 antibody). Arthritis Rheum. 50, S447 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR85","doi-asserted-by":"crossref","first-page":"44315","DOI":"10.1074\/jbc.M105446200","volume":"276","author":"KL Otipoby","year":"2001","unstructured":"Otipoby, K. L., Draves, K. E. & Clark, E. A. CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1. J. Biol. Chem. 276, 44315\u201344322 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnri1838_CR86","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","volume":"190","author":"F Mackay","year":"1999","unstructured":"Mackay, F. et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190, 1697\u20131710 (1999).","journal-title":"J. Exp. Med."},{"key":"BFnri1838_CR87","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","volume":"15","author":"JA Gross","year":"2001","unstructured":"Gross, J. A. et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 15, 289\u2013302 (2001).","journal-title":"Immunity"},{"key":"BFnri1838_CR88","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","volume":"404","author":"JA Gross","year":"2000","unstructured":"Gross, J. A. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995\u2013999 (2000).","journal-title":"Nature"},{"key":"BFnri1838_CR89","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1074-7613(04)00079-2","volume":"20","author":"R Lesley","year":"2004","unstructured":"Lesley, R. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20, 441\u2013453 (2004).","journal-title":"Immunity"},{"key":"BFnri1838_CR90","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker, K. P. et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253\u20133265 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR91","doi-asserted-by":"crossref","first-page":"S444","DOI":"10.1002\/art.21138","volume":"52","author":"W Stohl","year":"2005","unstructured":"Stohl, W. et al. Belimumab selectively modulates B-cell subpopulations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis Rheum. 52, S444 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnri1838_CR92","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1081-1206(10)61490-1","volume":"93","author":"J Stokes","year":"2004","unstructured":"Stokes, J. & Casale, T. B. Rationale for new treatments aimed at IgE immunomodulation. Ann. Allergy Asthma Immunol. 93, 212\u2013217 (2004).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"BFnri1838_CR93","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.4049\/jimmunol.171.4.1642","volume":"171","author":"Y Ebisuno","year":"2003","unstructured":"Ebisuno, Y. et al. Cutting edge: the B cell chemokine CXC chemokine ligand 13\/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph nodes and Peyer's patches and affects B cell trafficking across high endothelial venules. J. Immunol. 171, 1642\u20131646 (2003).","journal-title":"J. Immunol."},{"key":"BFnri1838_CR94","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1191\/0961203304lu1032oa","volume":"13","author":"PI Sidiropoulos","year":"2004","unstructured":"Sidiropoulos, P. I. & Boumpas, D. T. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13, 391\u2013397 (2004).","journal-title":"Lupus"},{"key":"BFnri1838_CR95","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumour necrosis factor \u03b1 inhibition. New Engl. J. Med. 353, 1114\u20131123 (2005).","journal-title":"New Engl. J. Med."},{"key":"BFnri1838_CR96","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.0105-2896.2005.00225.x","volume":"203","author":"JM Lindvall","year":"2005","unstructured":"Lindvall, J. M. et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol. Rev. 203, 200\u2013215 (2005).","journal-title":"Immunol. Rev."},{"key":"BFnri1838_CR97","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/13543784.13.7.743","volume":"13","author":"BR Wong","year":"2004","unstructured":"Wong, B. R., Grossbard, E. B., Payan, D. G. & Masuda, E. S. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin. Investig. Drugs 13, 743\u2013762 (2004).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnri1838_CR98","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O'Connor","year":"2004","unstructured":"O'Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91\u201398 (2004).","journal-title":"J. Exp. Med."},{"key":"BFnri1838_CR99","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/art.10763","volume":"48","author":"D Alarcon-Segovia","year":"2003","unstructured":"Alarcon-Segovia, D. et al. LJP 394 for the prevention of renal flare in systemic lupus erythematosus. Arthritis Rheum. 48, 442\u2013454 (2003).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nri1838","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nri1838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nri1838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:10:45Z","timestamp":1684455045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nri1838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,7]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["BFnri1838"],"URL":"https:\/\/doi.org\/10.1038\/nri1838","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,7]]}}}